Continuous light and L-NAME-induced left ventricular remodelling: Different protection with melatonin and captopril

Journal of Hypertension

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Simko, Fedor ^a   Pechanova, Olga ^b   Pelouch, Vaclav ^c,d   Krajcirovicova, Kristina ^a   Celec, Peter ^a   Palffy, Roland ^a   Bednarova, Kristina ^a   Vrankova, Stanislava ^b   Adamcova, Michaela ^c,e   Paulis, Ludovit ^a,b  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Center for Cardiovascular Research   (Czech Republic)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANGIOTENSIN CONVERTING ENZYME 2; CAPTOPRIL; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYPROLINE; MALONALDEHYDE; MELATONIN; N(G) NITROARGININE METHYL ESTER;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RIGHT VENTRICLE; HEART WEIGHT; HYPERTENSION; LIGHT EXPOSURE; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 77957255604     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000388489.28213.08     Document Type: Article

References (43)

1. Simko F. Pathophysiological principles of the relation between myocardial hypertrophy of the left ventricle and its regression [mini review]. Physiol Res 1994; 43:259-266.
2. Simko F. Left ventricular hypertrophy regression as a process with variable biological implications [review]. Can J Cardiol 1996; 12:507-513.
3. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Zanchetti A. Left ventricular hypertrophy and cardiovascular risk stratification: impact and costeffectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 2006; 24:1671-1677.
4. Zanchetti A. Hypertension: cardiac hypertrophy as a target of antihypertensive therapy. Nat Rev Cardiol 2010; 7:66-67.
5. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci 2005; 108:349-355.
6. Simko F, Matuskova J, Luptak I, Krajcirovicova K, Kucharska J, Gvozdjakova A, et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004; 74:1211-1224.
7. Simko F, Pelouch V, Torok J, Luptak I, Matuskova J, Pechanova O, et al. Protein remodeling of the heart ventricles in hereditary hypertriglyceridemic rat: effect of ACE-inhibition. J Biomed Sci 2005; 12:103-111.
8. Hoffman RA, Reiter RJ. Rapid pinealectomy in hamsters and other small rodents. Anat Rec 1965; 153:19-21.
9. Holmes SW, Sugden D. Proceedings: the effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol 1976; 56:360-361.
10. Cunnane SC, Manku MS, Oka M, Horrobin DF. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin. Can J Physiol Pharmacol 1980; 58:287-293.
11. Zanoboni A, Zanoboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sci 1967; 6:2327-2331.
12. Delibas N, Tuzmen N, Yonden Z, Altuntas I. Effect of functional pinealectomy on hippocampal lipid peroxidation, antioxidant enzymes and N-methyl-D-aspartate receptor subunits 2A and 2B in young and old rats. Neuro Endocrinol Lett 2002; 23:345-350.
13. Paulis L, Vazan R, Simko F, Pechanova O, Styk J, Babal P, et al. Morphological alterations and NO-synthase expression in the heart after continuous light exposure of rats. Physiol Res 2007; 56 (Suppl. 2):S71-S76.
14. Brown GM, Bar-Or A, Grossi D, Kashur S, Johannson E, Yie SM. Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. J Pineal Res 1991; 10:141-147.
15. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003; 58:10-19.
16. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2007; 44:16-25.
17. Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 1999; 83:1417-1419.
18. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 2009; 27 (Suppl. 6):S17-S20.
19. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment [mini review]. J Pineal Res 2007; 42:319-322.
20. Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens 2010; 28 (Suppl. 1):S7-S12.
21. Simko F, Pechanova O. Recent trends in hypertension treatment: perspectives from animal studies. J Hypertens 2009; (Suppl. 6): S1-S4
22. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res 2009; 47:127-133.
23. Pelouch V, Milerova M, Ostadal B, Samanek M, Hucin B. Protein profiling of human atrial and ventricular musculature: the effect of normoxaemia and hypoxaemia in congenital heart diseases. Physiol Res 1993; 42:235-242.
24. Pelouch V, Milerova M, Ostadal B, Hucin B, Samanek M. Differences between atrial and ventricular protein profiling in children with congenital heart disease. Mol Cell Biochem 1995; 147:43-49.
25. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29:225-229.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351-358.
27. Witko-Sarsat W, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64:82-91.
28. Vazan R, Janega P, Hojná S, Zicha J, Simko F, Pechá nová O, et al. The effect of continuous light exposure of rats on cardiac response to ischemia-reperfusion and NO-synthase activity. Physiol Res 2007; 56 (Suppl. 2):S63-S69.
29. Witte K, Grebmer W, Scalbert E, Delagrange P, Guardiola-Lemâtre B, Lemmer B. Effects of melatoninergic agonists on light-suppressed circadian rhythms in rats. Physiol Behav 1998; 65:219-224.
30. Briaud SA, Zhang BL, Sannajust F. Continuous light exposure and sympathectomy suppress circadian rhythm of blood pressure in rats. J Cardiovasc Pharmacol Ther 2004; 9:97-105.
31. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in nondipper hypertensive patients. Blood Press 2003; 12:19-24.
32. Pechanova O, Bernatova I, Pelouch V, Simko F. Protein remodeling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997; 29:3365-3374.
33. Bernatova I, Pechanova O, Pelouch V, Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 2000; 32:177-185.
34. Simko F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodeling in spontaneously hypertensive rats. J Hypertens 2009; 27 (Suppl. 6):S5-S10.
35. Paulis L, Pechanova O, Zicha J, Krajcirovicova K, Csizmadiova Z, Potacova A, et al. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of N-G-nitro-L-arginine-methyl ester hypertensive rats. J Hypertens 2009; 27 (Suppl. 6):S11-S16.
36. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 2004; 43:716-719.
37. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001; 38:588-591.
38. Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 1999; 48:1-8.
39. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56:671-684.
40. Pechanova O, Zicha J, Paulis L, Zenebe W, Dobesova Z, Kojsova S, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 2007; 561:129-136.
41. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37:1047-1052.
42. Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptorindependent actions. Adv Med Sci 2007; 52:11-28.
43. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15:43-50.